<DOC>
	<DOCNO>NCT02593071</DOCNO>
	<brief_summary>This study enroll subject receive RSV F vaccine placebo earlier study ( RSV-E-201 , Year 1 ) re-randomize receive either vaccine placebo second season . This design permit evaluation safety immunogenicity revaccination second RSV season , safety immunogenicity revaccination two year .</brief_summary>
	<brief_title>Safety Immunogenicity RSV-F Vaccine Older Adults Previously Treated With Same Vaccine Placebo Prior Year .</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Males females ≥60 year age veterans RSVE201 clinical trial ambulatory live community residential facility provide minimal assistance , subject primarily responsible selfcare activity daily live . Subjects may one chronic medical diagnosis , clinically stable assess : Absence change medical therapy within one month due treatment failure toxicity , Absence medical event qualify SAEs within two month , Absence know , current , lifelimiting diagnosis , opinion investigator , render survival trial completion unlikely . 2 . Willing able ( physical cognitive basis ) give inform consent prior study enrollment . 3 . Able comply study requirement , include access transportation study visit . The investigator may use his/her discretion ass potential ability willingness comply base performance prior trial , RSVE201 . 4 . Access inbound outbound communication telephone caregiver study staff . 1 . Participation research involve investigational product ( drug / biologic / device ) within 45 day plan date first vaccination , exception participation precede study RSVE201 . 2 . History serious reaction prior vaccination , GuillainBarré syndrome ( GBS ) within 6 week prior influenza immunization , withdrawal precede RSVE201 clinical trial due adverse event deem test articlerelated advice investigator . 3 . Receipt vaccine IIV 4 week precede study vaccination ; RSV vaccine time unless administer preceding study , RSVE201 . 4 . Any known suspected immunosuppressive condition , acquire congenital , determined history and/or physical examination . 5 . Chronic administration ( define 14 continuous day ) immunosuppressant immunemodifying drug within 6 month prior administration study vaccine . An immunosuppressant dose glucocorticoid define systemic dose ≥10mg prednisone per day equivalent . The use topical , inhaled , nasal glucocorticoid permit . 6 . Administration immunoglobulins and/or blood product within 3 month precede administration study vaccine study . 7 . Acute disease time enrollment ( define presence moderate severe illness without fever , oral temperature ≥38.0°C plan day vaccine administration ) . 8 . Known disturbance coagulation . Potential subject receive aspirin , clopidogrel , prasugrel , dipyridamole , dabigatran , apixaban , rivaroxaban warfarin good control cardiovascular prophylaxis prophylaxis thromboembolic disease stroke set atrial fibrillation NOT exclude . 9 . Suspicion recent history ( within one year plan vaccination ) alcohol substance abuse . 10 . Any condition opinion investigator would pose health risk subject enrol could interfere evaluation vaccine interpretation study result ( include neurologic , cognitive , psychiatric condition deem likely impair quality study compliance safety reporting ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>